Introduction
Throughout the history of the world, the ones who had confronted the bitterest face of poverty and war had always been the women. As known poverty and war affects human health either directly or indirectly, the effects of this condition on health and status of women in the society should not be ignored. This study intends to cast light on the effects of war and poverty on the reproductive health of women. For this purpose, the face of war affecting the women, the problem of immigration, inequalities in distribution of income based on gender and the effects of all these on the reproductive health of women will be addressed.
War and Women's Health
Famine, synonymous with war and poverty, is clearer for women; war means deep disadvantages such as full destruction, loss of future and uncertainty for women. Wars are conflicts that destroy families, societies and cultures that negatively affect the health of community and cause violation of human rights. According to the data of World Health Organization (WHO) and World Bank, in 2002 wars had been among the first ten reasons which killed the most and caused disabilities. Civil losses are at the rate of 90% within all losses (1) . War has many negative effects on human health. One of these is its effect of shortening the average human life. According to the data of WHO, the average human life is 68.1 years for males and 72.7 years for females. It is being thought that severe military conflicts in Africa shorten the expected lifetime for more than 2 years. In general, WHO had calculated that 269 thousand people had died in 1999 due to the effect of wars and that loss of 8.44 million healthy years of life had occurred (2, 3) . Wars negatively affect the provision of health services. Health institutions such as hospitals, laboratories and health centers are direct targets of war. Moreover, the wars cause the migration of qualified health employees, and thus the health services hitches. Assessments made indicate that the effect of destruction in the infrastructure of health continues for 5-10 years even after the finalization of conflicts (3) . Due to resource requirements in the restructuring investments after war, the share allocated to health has decreased (1).
Mortalities and Morbidities
The ones who are most affected from wars are women and children. While deaths depending on direct violence affect the male population, the indirect deaths kill children, women and elders more. In Iraq between 1990-1994, infant deaths had shown this reality in its more bare form with an increase of 600% (4). The war taking five years increases the child deaths under age of 5 by 13%. Also 47% of all the refugees in the world and 50% of asylum seekers and displaced people are women and girls and 44% refugees and asylum seekers are children under the age of 18 (5) . As the result of wars and armed conflicts, women are Abstract War and poverty are 'extraordinary conditions created by human intervention' and 'preventable public health problems. ' War and poverty have many negative effects on human health, especially women's health. Health problems arising due to war and poverty are being observed as sexual abuse and rape, all kinds of violence and subsequent gynecologic and obstetrics problems with physiological and psychological courses, and pregnancies as the result of undesired but forced or obliged marriages and even rapes. Certainly, unjust treatment such as being unable to gain footing on the land it is lived (asylum seeker, refugee, etc.) and being deprived of social security, citizenship rights and human rights brings about the deprivation of access to health services and of provision of service intended for gynecology and obstetrics. The purpose of this article is to address effects of war and poverty on the health of reproduction of women and to offer scientific contribution and solutions. Keywords: Poverty, Reproductive health, War 298 of mother's homodynamic situation and 2) the patients request to be excluded. Written informed consent was obtained from the participants before their participation in the study. The participants were selected for each group based on tetra blocking method ( Figure 1 ).
For the oxytocin group, 50 units of oxytocin was dissolved in 30 mL of normal saline and for the misoprostol group, 800 µg of the compound was dissolved in 30 mL of normal saline. Then they were injected into the umbilical veins of the participants. This method was based on the study of Harara et al (12) . Vein oxytocin was not injected unless the placenta was delivered completely.
The data were obtained from a researcher-made questionnaire which was validated by a group of obstetricians and gynecologists. The study consequences, final time of placenta delivery and hemoglobin drop were recorded after the injections. The participants and physicians were unaware of the used medicines (the study was double-blinded). The following formula was used to calculate the sample size: n=Z 2 P(1-P)/d 2 In this formula: as in previous studies (17) , P= prevalence of retained placenta, 3% = 0.03; d = sample volume estimation accuracy, 0.1; Z= 95% confidence interval (α=5%), 1.96.
Considering the significance level of 0.05, at least 22 samples were required in each group. The considered variables were as follows: mother's age, gestational age, parturition and pregnancy frequencies, abortion, retained placenta, curettage and caesarian history, taking misoprostol or oxytocin, placental delivery time and hemoglobin. The data were analyzed using statistical package for social sciences (SPSS) software version 16.0 (Chicago, IL, USA). Frequency and percentage were calculated for the qualitative variables and mean and standard deviation for the quantitative variables. Chi-square, Fisher's exact test and McNemar test were used to analyze qualitative data. Quantitative data were analyzed by T-test and Mann-Whitney U test.
Results
The participants' mean age was 30 ± 5 years old (ranging between 18 and 48 years old). The mean of gestational age was 35± 5 weeks (ranging between 24 and 42 weeks). There were 22 participants in each group (Table 1) .
There was no significant difference between injecting misoprostol or oxytocin in spontaneous placental delivery in the mothers younger than 30 years old (P = 0.08). However, there was a significant difference between injecting misoprostol and oxytocin in the mothers older than 30 years old. Totally, spontaneous placental 10 delivery was more in the misoprostol group than that in the oxytocin group (P = 0.03; Table 2 ). There was no significant difference in placental delivery time between the 2 groups (P = 0.28) ( Table 3) .
Figure Legend
There was no significant difference in placental delivery between the participants with less than 30 gestational age in both groups. But there was a significant difference in the women more than 30 gestational age. The probability of placental delivery was more in the use of misoprostol compared to the use of oxytocin (P = 0.002; Table 4 ).
There was a significant difference between the participants with less than three times of pregnancies in both groups in placental delivery (P = 0.006). The probability of placental delivery was 14 times more in the misoprostol group (confidence interval: 1.5-147). However, there was no significant difference in placental delivery in both groups between the participants with less than three times of pregnancies (P = 0.05; Table 5 ).
There was no significant difference between both groups regarding the placental delivery in the participants that had an abortion history, retained placenta, curettage, caesarian and pregnancy more than three times. However, among those who did not have these histories and had less than three pregnancies, the significant difference in placental delivery was nine times more in the misoprostol group compared to the oxytocin group (P = 0.02). A significant difference was observed in hemoglobin level before and after the intervention in both groups, but there was less hemoglobin drop in the misoprostol group.
Discussion
Our results about the association of mother's age with the 2 treatments are similar to the results of Rogers and colleagues in which the spontaneous placental delivery with the umbilical vein injection of misoprostol was more than that with the umbilical vein injection of oxytocin (13) . In the studies of Rajab et al (14) and Harara et al (12) , spontaneous placental delivery was more in misoprostol group compared to placebo group. However, in these studies the differences were not significant. In the study of van Stralen et al, spontaneous placental delivery was also not significantly different between misoprostol and placebo groups. This might be because of oral administration of misoprostol or considering retained placenta for 60 minutes (15) .
Regarding placental delivery time, there was no significant difference in our study which is inconsistent with the results of Harara et al. In their study, this time was shorter for the misoprostol group. This might be because of the difference in the concentration of injected oxytocin in the 2 studies. In a study by Eldaly, it was revealed that the placental delivery time had decreased efficiently when umbilical vein injection of oxytocin was associated with rectal use of misoprostol (16) . These differences in results can also be because of the number of participants. Non-significant difference in the effect of used medicines between the participants who had an abortion, retained placenta, curettage, caesarian and pregnancy more than three times could be because of vaginal scars caused by previous traumas. This might increase placenta adherence and interfere in the applied medicines. However, the effect of misoprostol is more than that of oxytocin in the cases who have no trauma history and therefore placenta adherence to the uterine wall is normal.
Less hemoglobin drop among misoprostol group in our results was similar to the results of Bellad et al (10), but different from those of Atukunda et al and Rajaei et al (11, 17) . In these 2 studies, hemoglobin drop was not significantly different between their study groups. But the concentration of medicine and method of administration were different in our study which can be the reason for the differences of the results.
Conclusions
Umbilical vein injection of misoprostol is more effective in treating elongated third stage labor (retained placenta for more than 30 minutes) and also in decreasing bleeding, especially in the cases without vaginal trauma history, compared to umbilical vein injection of oxytocin. Therefore, the use of this medicine is strongly recommended.
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